Over this period, Pharmaceuticals shows 4 positive, 0 neutral and 0 negative news signals across its constituents. The auto-generated sector insight (top drivers with direction + rationale) appears here once the analysis worker has processed enough items.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Showing 4 stories from March 2026
Show allGlaxoSmithKline Pakistan grew 2025 net profit 53 percent to Rs10.03 billion on 8 percent higher sales, helped by price adjustments and a better product mix. It lifted its total dividend to Rs17 per share.
A dispute over drug price fixation by the Drug Regulatory Authority of Pakistan (DRAP) has caused several essential medicines and vaccines to disappear from the market, negatively impacting pharmaceutical companies.
Reports indicate a potential shortage of essential medicines and formula milk, which could significantly affect pharmaceutical companies and food producers relying on imported inputs or selling these products.
Haleon Pakistan, the consumer health company behind brands like Panadol and Sensodyne, grew 2025 net profit 39 percent to Rs6.37 billion on 16 percent revenue growth and tight cost control. It declared a Rs15 per share dividend.
How news sentiment on the Pharmaceuticals sector has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
